Oramed Pharmaceuticals Stock Alpha and Beta Analysis
| ORMP Stock | USD 3.68 0.24 6.98% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Oramed Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Oramed Pharmaceuticals over a specified time horizon. Remember, high Oramed Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Oramed Pharmaceuticals' market risk premium analysis include:
Beta 2.08 | Alpha 0.64 | Risk 3.43 | Sharpe Ratio 0.27 | Expected Return 0.94 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Oramed Pharmaceuticals Backtesting, Oramed Pharmaceuticals Valuation, Oramed Pharmaceuticals Correlation, Oramed Pharmaceuticals Hype Analysis, Oramed Pharmaceuticals Volatility, Oramed Pharmaceuticals History and analyze Oramed Pharmaceuticals Performance. Oramed Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Oramed Pharmaceuticals market risk premium is the additional return an investor will receive from holding Oramed Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Oramed Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Oramed Pharmaceuticals' performance over market.| α | 0.64 | β | 2.08 |
Oramed Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Oramed Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Oramed Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Oramed Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Oramed Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Oramed Pharmaceuticals shares will generate the highest return on investment. By understating and applying Oramed Pharmaceuticals stock market price indicators, traders can identify Oramed Pharmaceuticals position entry and exit signals to maximize returns.
| Price Series Summation | ||
| Price Series Division | ||
| Price Ceiling Movement | ||
| Tangent Of Price Series | ||
| Aroon Oscillator | ||
| Aroon Oscillator | ||
| Kaufman Adaptive Moving Average | ||
| Bollinger Bands | ||
| Rickshaw Man | ||
| Harami Cross Pattern |
Oramed Pharmaceuticals Return and Market Media
The median price of Oramed Pharmaceuticals for the period between Sun, Oct 19, 2025 and Sat, Jan 17, 2026 is 2.54 with a coefficient of variation of 15.19. The daily time series for the period is distributed with a sample standard deviation of 0.39, arithmetic mean of 2.55, and mean deviation of 0.32. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 3000 shares by Mayer Arie of Oramed Pharmaceuticals at 25.6 subject to Rule 16b-3 | 11/07/2025 |
2 | Is Oramed Pharmaceuticals Inc. stock vulnerable to rate hikes - July 2025 Catalysts Free Safe Entry Trade Signal Reports - newser.com | 11/10/2025 |
3 | Will Oramed Pharmaceuticals Inc. stock maintain strong growth - Earnings Recap Report Expert Approved Momentum Trade Ideas - newser.com | 11/13/2025 |
4 | Lifeward Ltd. Reports Third Quarter 2025 Financial Results | 11/14/2025 |
5 | Oramed Pharmaceuticals GAAP EPS of 1.26 | 11/17/2025 |
6 | What market sentiment indicators show for Oramed Pharmaceuticals Inc. stock - Market Risk Report Safe Entry Momentum Stock Tips - newser.com | 11/19/2025 |
7 | ORMP Advancing Clinical Activities, Generating Gains From Investment Portfolio, New Rights Plan Adopted | 11/24/2025 |
8 | Oramed Pharmaceuticals And 2 Other Promising Penny Stocks To Watch | 12/16/2025 |
9 | Acquisition by Kidron Nadav of 109000 shares of Oramed Pharmaceuticals subject to Rule 16b-3 | 12/30/2025 |
10 | Acquisition by Avraham Gabay of 19000 shares of Oramed Pharmaceuticals subject to Rule 16b-3 | 12/31/2025 |
11 | Oramed Receives 18 Million Payment from Scilex Holdings, Bringing Current Returns to 118 Million Board Approves Dividend Payments | 01/07/2026 |
12 | 3 Promising Penny Stocks With Market Caps Under 200M | 01/14/2026 |
About Oramed Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Oramed or other stocks. Alpha measures the amount that position in Oramed Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Oramed Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Oramed Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Oramed Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Oramed Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Oramed Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Oramed Pharmaceuticals' management manipulating its earnings.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Oramed Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Oramed Stock Analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.